FDA Approves NovoSeven Coagulation Factor VIIa (Recombinant) for Acquired Hemophilia
PRINCETON, N.J., October 17, 2006 -- The United States Food and Drug Administration (FDA) has approved a new indication for NovoSeven Coagulation Factor VIIa (Recombinant), making it the first and only recombinant therapy approved for the treatment of acquired hemophilia, a rare and potentially fatal bleeding disorder. As a recombinant therapy, NovoSeven is not plasma-derived and poses no risk of human viral transmission through its use.
The FDA approved NovoSeven for treatment of bleeding episodes in patients with acquired hemophilia, and in the prevention of bleeding in surgical interventions or invasive procedures in patients with acquired hemophilia.
"Novo Nordisk is proud of our dedication to hemostasis research and development, especially for rare bleeding disorders. This acquired hemophilia indication is in line with our core commitment to provide innovative therapies to people who need them," said Martin Soeters, president of Novo Nordisk Pharmaceuticals, Inc.
NovoSeven was first introduced in 1999, and is currently indicated for use in treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX and for treatment of bleeding episodes in patients with congenital Factor VII deficiency. It is also indicated for prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX and in patients with congenital Factor VII deficiency.
"The approval of NovoSeven for use in patients with acquired hemophilia offers an effective choice for treating this life-threatening disorder," said Craig M. Kessler, MD, Professor of Medicine and Pathology, Georgetown University Medical Center. "Its use will help physicians to meet the main objective in treating the disorder -- stopping the bleeding episode."
About Acquired Hemophilia
Acquired hemophilia appears in up to 4 persons per million per year. It disrupts the body’s natural blood clotting process, causing spontaneous, uncontrolled bleeding to occur, most often, in the skin and soft tissues. It is often difficult to recognize and can be fatal in up to 22 percent of patients. Unlike classical hemophilia, acquired hemophilia is not inherited.
With acquired hemophilia, the body produces antibodies against its own Factor VIII or Factor IX blood clotting proteins that are essential to the formation of an effective blood clot. The disorder can occur in men or women (median age 64). Often, an underlying medical condition is involved. Associations with autoimmune conditions, cancer, use of certain drugs and pregnancy (although rare) have been recognized. In about half of all cases, there is no underlying cause.
About the Data
Pooled data analysis from the Compassionate Use Programs and Hemophilia and Thrombosis Research Society (HTRS) registry show that NovoSeven demonstrated overall efficacy -- i.e., "effective" and "partially effective" outcomes -- in the majority (78 percent) of patients treated for bleeding episodes. This translates into 77 percent efficacy seen in the Compassionate Use Programs and 83 percent efficacy in the HTRS registry.
NovoSeven is an activated recombinant version of Factor VII which is functionally indistinguishable from naturally occurring activated Factor VII. The product is currently approved for treatment of bleeding episodes in congenital hemophilia patients with inhibitors to Factor VIII or Factor IX and in patients with acquired hemophilia; the prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX and in patients with acquired hemophilia; treatment of bleeding episodes in patients with congenital Factor VII deficiency; and prevention of bleeding in surgical interventions or invasive procedures in patients with congenital Factor VII deficiency.
NovoSeven is produced in baby hamster kidney cells which have been genetically engineered to express recombinant Factor VII. Because no human albumin is added as a stabilizer, nor is any other human proteins used during manufacturing or added to the final product, there is no risk of human blood- borne pathogen transmission.
For prescribing information, please visit www.novoseven-us.com.
Most common adverse events: pyrexia, hemorrhage, injection site reaction, arthralgia, headache, hypertension, hypotension, nausea, vomiting, pain, edema and rash. Patients with disseminated intravascular coagulation (DIC), advanced atherosclerotic disease, crush injury, septicemia, or concomitant treatment with activated or nonactivated prothrombin complex concentrates (aPCCs/PCCs) may have a potential risk of developing thrombotic events in association with NovoSeven treatment. Contraindicated in patients with known hypersensitivity to NovoSeven or mouse, hamster, or bovine protein. The risk of potential interaction between NovoSeven and coagulation factor concentrates has not been evaluated. Simultaneous use of aPCCs/PCCs, should be avoided. Serious adverse events which may or may not have been related to the use of NovoSeven in acquired hemophilia (10 of 139 patients in the Compassionate Use Program, HTRS registry, and the published literature) may include thrombotic serious adverse events. Serious adverse events which may or may not have been related to the use of NovoSeven occurred in 14 of 298 patients with hemophilia A or B with inhibitors in the initial clinical program.
Source: Novo Nordisk
Posted: October 2006